Fig. 8: Therapeutic efficacy of Z1780628919 in Ang II-induced hypertension and vascular damage.
From: Targeting GPR39 in structure-based drug discovery reduces Ang II-induced hypertension
a Blood pressure measurements (systolic pressure, diastolic pressure and mean arterial pressure; tail artery measurements, n = 6) in saline, Ang II, Z1780628919, and Ang II + Z1780628919 treated mice. b Assessment of fibrosis in mouse aortic vessels (n = 6) using Masson’s trichrome staining and quantification of fibrotic areas. c Protein levels of fibrosis markers (α-SMA, TGF-β and COL-1, n = 6) in the aortic vessels. GAPDH served as the loading control. d Analysis of apoptosis marker proteins (eNOS, p-eNOS, Bax, Bcl-2, Caspase-3 and Cleaved caspase-3, n = 6) in the aortic vessels. GAPDH used as a loading control. e, f TUNEL staining for apoptosis visualization in aortic vessels of mice across the four groups (TUNEL, green; CD31, red; DAPI, blue; n = 6; Scale, 50 μm). g, h 8-OHdG staining to detect oxidative stress in aortic vessels of the four groups (8-OHdG, green; CD31, red; DAPI, blue; n = 6; Scale, 50 μm). i, j DHE staining for oxidative stress assessment in aortic vessels of the four groups (DHE, green; CD31, red; DAPI, blue; n = 6; Scale, 50 μm). k–m mRNA levels of inflammation markers (IL-1, IL-6 and TNF-α, n = 6) in the aortic vessels. GAPDH as the loading control. Data are expressed as the mean ± SEM. Statistical significance is denoted as NS, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001.
